# BizDataDive: Why does a new drug require joint R&D? — retained record

> Retained china-news record from china-news:cgtn-business.

Canonical: https://highsignal.app/data/records/2bdc34baab890f54

[← sources](https://highsignal.app/data)


source: [china-news](https://highsignal.app/data/china-news) (china-news:cgtn-business)  published 2026-09-20 13:00 ingested 2026-09-22 02:52

[original source ↗](https://news.cgtn.com/news/2026-09-20/BizDataDive-Why-does-a-new-drug-require-joint-R-D--1Qzb2NQAKv6/p.html?UTM_Source=cgtn&UTM_Medium=rss&UTM_Campaign=Business)

## retained text



```
Choose your language
                    
                By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
                            
                            I agree
                        
                    
                        Economy
                    
                    
    21:00, 20-Sep-2026
                    
                
                
                        01:56
                    
                    
            China has a third of the world's innovative drugs-in-development, while the US contributes 55% of global biopharma R&D investment. When these strengths meet, multi-billion-dollar partnerships follow—and patients worldwide benefit.
In this episode, we explore why drug development knows no borders.
                Search Trends
            
            DOWNLOAD OUR APP
            
            
            Copyright © 2026 CGTN. 
                    京ICP备20000184号
                京公网安备 11010502050052号
                        
                        互联网新闻信息许可证10120180008
                    Disinformation report hotline: 010-85061466
```



document fetched 2026-09-22 02:52 · canonical https://news.cgtn.com/news/2026-09-20/BizDataDive-Why-does-a-new-drug-require-joint-R-D--1Qzb2NQAKv6/p.html
